Figure 7.

(A) Isolated mice mesenteric microvessels obtained from untreated C57BL/6 mice were pre-contracted with 3 μmol/L NA and submitted to cumulative concentrations of the endothelium-dependent vasodilator ACh, (10 nmol/L to 10 μmol/L) in the absence of any previous treatment (Control) or after receiving 50 ng/mL visfatin/eNampt, 100 nmol/L MCC 950, or both visfatin/eNampt plus MCC 950. (B) Isolated mice mesenteric microvessels were obtained from C57BL/6 mice infused during 7 days by osmotic mini-pumps with saline solution, visfatin/eNampt (100 ng/kg/day), and receiving also the i.p. administration of MCC 950 (10 mg/kg) or analogous amounts of saline on days 2, 4, and 6. The vessels were pre-contracted with NA and submitted to cumulative concentrations of ACh. (C) Isolated mice mesenteric microvessels from untreated C57BL/6 mice submitted to ACh in Control conditions or after receiving 50 ng/mL visfatin/eNampt, 100 µg/mL anakinra, or both visfatin/eNampt plus anakinra. (D) Isolated mice mesenteric microvessels obtained from C57BL/6 mice infused with saline solution or visfatin/eNampt for 7 days and receiving also i.p. anakinra (100 mg/kg/day) or analogous amounts of saline during the last 3 days before sacrifice. The curves (mean ± SEM) are expressed as the percentage of the previous NA-evoked contraction, which is indicated in the Tables S1 and S2, as well as the respective pEC₅₀ values. For every curve, 5 to 11 segments were used, obtained from 3 to 8 different animals. *p < 0.05 vs respective control or saline. #p < 0.05 vs respective visfatin/eNampt.